143 related articles for article (PubMed ID: 27308494)
1. BRAF inhibitors in colorectal cancer: Toward a differentiation therapy?
Herr R; Brummer T
Mol Cell Oncol; 2015; 2(4):e1002709. PubMed ID: 27308494
[TBL] [Abstract][Full Text] [Related]
2. BRAF inhibition upregulates a variety of receptor tyrosine kinases and their downstream effector Gab2 in colorectal cancer cell lines.
Herr R; Halbach S; Heizmann M; Busch H; Boerries M; Brummer T
Oncogene; 2018 Mar; 37(12):1576-1593. PubMed ID: 29326440
[TBL] [Abstract][Full Text] [Related]
3. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents.
Mao M; Tian F; Mariadason JM; Tsao CC; Lemos R; Dayyani F; Gopal YN; Jiang ZQ; Wistuba II; Tang XM; Bornman WG; Bollag G; Mills GB; Powis G; Desai J; Gallick GE; Davies MA; Kopetz S
Clin Cancer Res; 2013 Feb; 19(3):657-67. PubMed ID: 23251002
[TBL] [Abstract][Full Text] [Related]
4. Acquired resistance to BRAF inhibitors is mediated by BRAF splicing variants in BRAF V600E mutation-positive colorectal neuroendocrine carcinoma.
Shimizu Y; Maruyama K; Suzuki M; Kawachi H; Low SK; Oh-Hara T; Takeuchi K; Fujita N; Nagayama S; Katayama R
Cancer Lett; 2022 Sep; 543():215799. PubMed ID: 35724767
[TBL] [Abstract][Full Text] [Related]
5. Wnt/β-Catenin Pathway Activation Mediates Adaptive Resistance to BRAF Inhibition in Colorectal Cancer.
Chen G; Gao C; Gao X; Zhang DH; Kuan SF; Burns TF; Hu J
Mol Cancer Ther; 2018 Apr; 17(4):806-813. PubMed ID: 29167314
[TBL] [Abstract][Full Text] [Related]
6. Yes-activated protein promotes primary resistance of
Su M; Zhan L; Zhang Y; Zhang J
J Gastrointest Oncol; 2021 Jun; 12(3):953-963. PubMed ID: 34295548
[TBL] [Abstract][Full Text] [Related]
7. Targeting CDK1 and MEK/ERK Overcomes Apoptotic Resistance in BRAF-Mutant Human Colorectal Cancer.
Zhang P; Kawakami H; Liu W; Zeng X; Strebhardt K; Tao K; Huang S; Sinicrope FA
Mol Cancer Res; 2018 Mar; 16(3):378-389. PubMed ID: 29233910
[TBL] [Abstract][Full Text] [Related]
8. A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAF
Ruiz-Saenz A; Atreya CE; Wang C; Pan B; Dreyer CA; Brunen D; Prahallad A; Muñoz DP; Ramms DJ; Burghi V; Spassov DS; Fewings E; Hwang YC; Cowdrey C; Moelders C; Schwarzer C; Wolf DM; Hann B; VandenBerg SR; Shokat K; Moasser MM; Bernards R; Gutkind JS; van 't Veer LJ; Coppé JP
Nat Cancer; 2023 Feb; 4(2):240-256. PubMed ID: 36759733
[TBL] [Abstract][Full Text] [Related]
9. MAPK inhibitors induce serine peptidase inhibitor Kazal type 1 (SPINK1) secretion in BRAF V600E-mutant colorectal adenocarcinoma.
Räsänen K; Dang KX; Mustonen H; Ho TH; Lintula S; Koistinen H; Stenman UH; Haglund C; Stenman J
Mol Oncol; 2018 Feb; 12(2):224-238. PubMed ID: 29193645
[TBL] [Abstract][Full Text] [Related]
10. Molecular mechanisms underlying the resistance of BRAF V600E-mutant metastatic colorectal cancer to EGFR/BRAF inhibitors.
Xu T; Wang X; Wang Z; Deng T; Qi C; Liu D; Li Y; Ji C; Li J; Shen L
Ther Adv Med Oncol; 2022; 14():17588359221105022. PubMed ID: 35747165
[TBL] [Abstract][Full Text] [Related]
11. Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer.
Coffee EM; Faber AC; Roper J; Sinnamon MJ; Goel G; Keung L; Wang WV; Vecchione L; de Vriendt V; Weinstein BJ; Bronson RT; Tejpar S; Xavier RJ; Engelman JA; Martin ES; Hung KE
Clin Cancer Res; 2013 May; 19(10):2688-98. PubMed ID: 23549875
[TBL] [Abstract][Full Text] [Related]
12. 3'-Deoxy-3'-18F-fluorothymidine PET predicts response to (V600E)BRAF-targeted therapy in preclinical models of colorectal cancer.
McKinley ET; Smith RA; Zhao P; Fu A; Saleh SA; Uddin MI; Washington MK; Coffey RJ; Manning HC
J Nucl Med; 2013 Mar; 54(3):424-30. PubMed ID: 23341544
[TBL] [Abstract][Full Text] [Related]
13. MAP2K1 Mutation in Colorectal Cancer Patients: Therapeutic Challenge Using Patient-Derived Tumor Cell Lines.
Kim JE; Kim KK; Kim SY; Lee J; Park SH; Park JO; Park YS; Lim HY; Kang WK; Kim ST
J Cancer; 2017; 8(12):2263-2268. PubMed ID: 28819429
[No Abstract] [Full Text] [Related]
14. Development of small-molecule therapeutics and strategies for targeting RAF kinase in BRAF-mutant colorectal cancer.
Pan JH; Zhou H; Zhu SB; Huang JL; Zhao XX; Ding H; Pan YL
Cancer Manag Res; 2018; 10():2289-2301. PubMed ID: 30122982
[TBL] [Abstract][Full Text] [Related]
15. BCL-X
Jenkins LJ; Luk IY; Chionh F; Tan T; Needham K; Ayton J; Reehorst CM; Vukelic N; Sieber OM; Mouradov D; Gibbs P; Williams DS; Tebbutt NC; Desai J; Hollande F; Dhillon AS; Lee EF; Merino D; Fairlie WD; Mariadason JM
Cell Death Dis; 2024 Mar; 15(3):183. PubMed ID: 38429301
[TBL] [Abstract][Full Text] [Related]
16. Combined BRAF, EGFR, and MEK Inhibition in Patients with
Corcoran RB; André T; Atreya CE; Schellens JHM; Yoshino T; Bendell JC; Hollebecque A; McRee AJ; Siena S; Middleton G; Muro K; Gordon MS; Tabernero J; Yaeger R; O'Dwyer PJ; Humblet Y; De Vos F; Jung AS; Brase JC; Jaeger S; Bettinger S; Mookerjee B; Rangwala F; Van Cutsem E
Cancer Discov; 2018 Apr; 8(4):428-443. PubMed ID: 29431699
[TBL] [Abstract][Full Text] [Related]
17. BRAF V600E is a determinant of sensitivity to proteasome inhibitors.
Zecchin D; Boscaro V; Medico E; Barault L; Martini M; Arena S; Cancelliere C; Bartolini A; Crowley EH; Bardelli A; Gallicchio M; Di Nicolantonio F
Mol Cancer Ther; 2013 Dec; 12(12):2950-61. PubMed ID: 24107445
[TBL] [Abstract][Full Text] [Related]
18. Mutant BRAF Upregulates MCL-1 to Confer Apoptosis Resistance that Is Reversed by MCL-1 Antagonism and Cobimetinib in Colorectal Cancer.
Kawakami H; Huang S; Pal K; Dutta SK; Mukhopadhyay D; Sinicrope FA
Mol Cancer Ther; 2016 Dec; 15(12):3015-3027. PubMed ID: 27765849
[TBL] [Abstract][Full Text] [Related]
19. BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers.
Tang Z; Yuan X; Du R; Cheung SH; Zhang G; Wei J; Zhao Y; Feng Y; Peng H; Zhang Y; Du Y; Hu X; Gong W; Liu Y; Gao Y; Liu Y; Hao R; Li S; Wang S; Ji J; Zhang L; Li S; Sutton D; Wei M; Zhou C; Wang L; Luo L
Mol Cancer Ther; 2015 Oct; 14(10):2187-97. PubMed ID: 26208524
[TBL] [Abstract][Full Text] [Related]
20. MUC1-C is necessary for SHP2 activation and BRAF inhibitor resistance in BRAF(V600E) mutant colorectal cancer.
Morimoto Y; Yamashita N; Hirose H; Fushimi A; Haratake N; Daimon T; Bhattacharya A; Ahmad R; Suzuki Y; Takahashi H; Kufe DW
Cancer Lett; 2023 Apr; 559():216116. PubMed ID: 36878307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]